-
{{ listItem.name }}快速筛选药品，用摩熵药筛
微信扫一扫-立即使用
-
产品立项评估及管线规划
-
数据定制服务
-
产业/行业调研
-
市场洞察咨询服务
-
报告大厅
已收录 68518 份 -
摩熵说直播
最新改良型新药及创新药立项开发
- GLP-1
Amendment of the Enforcement Regulations of the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics related to Reprocessed Single-Use Medical Devices (R-SUDs)
2017-07-31
PSEHB Notification No. 0731-7
法律行政法规
日本
现行有效
/
日本医疗器械审评审批机构(PMDA)
最新政策法规资讯
-
-
-
政策法规解析 创新药临床审批 政策变动 采集意见
药通社2025-06-17
-
医药器械 政策解析 采集 市场分析
摩熵医械2025-06-03
-
政策解析 宠物医疗 驱虫药
药融圈2025-05-29
-
医保局 政策法规 三类医用耗材 采购新规
摩熵器械2025-05-28
-
FDA 临床试验 CGT 药物审评审批 法案
生物药大时代2025-05-19
-
国家药品集采 政策 药企 药品信息变更
药通社2025-02-20
-
医用耗材 医用耗材集采 集采新规
tyc7111cc太阳成集团2025-01-08
-
医保 医疗保障工作 医保改革
tyc7111cc太阳成集团2024-12-17
最新法律行政法规
-
国务院关于加强监管防范风险推动保险业高质量发展的若干意见
2024-09-11
-
推动大规模设备更新和消费品以旧换新行动方案
2024-03-18
-
人体器官捐献和移植条例
2023-12-14
-
支持北京深化国家服务业扩大开放综合示范区建设工作方案
2023-11-23
-
国务院关于推进普惠金融高质量发展的实施意见
2023-10-11
-
社会保险经办条例
2023-09-01
-
国务院关于做好自由贸易试验区第七批改革试点经验复制推广工作的通知
2023-07-10
-
Points to Consider for Informed Consent Using Electromagnetic Means in Clinical Trials and Post-marketing Clinical Trials
2023-03-30
-
数字中国建设整体布局规划
2023-02-27
-
中共中央 国务院关于做好2023年全面推进乡村振兴重点工作的意见
2023-02-13
-
中共中央 国务院印发《质量强国建设纲要》
2023-02-07
-
加强当前农村地区新型冠状病毒感染疫情防控工作方案
2022-12-31
-
关于进一步优化落实新冠肺炎疫情防控措施的通知
2022-12-07
-
关于进一步完善和落实积极生育支持措施的指导意见
2022-08-16
-
Dr. Yasuhiro Fujiwara, Chief Executive of PMDA, re-elected Vice Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA) (News Release)
2022-07-19
同部门最新法律行政法规
-
Points to Consider for Informed Consent Using Electromagnetic Means in Clinical Trials and Post-marketing Clinical Trials
2023-03-30
-
Dr. Yasuhiro Fujiwara, Chief Executive of PMDA, re-elected Vice Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA) (News Release)
2022-07-19
-
Procedure for Remote Inspection as a Part of Compliance Inspection on Drugs and Regenerative Medical Products
2022-05-25
-
Amendment to “Basic Principles on Global Clinical Trials (Reference Cases)”
2021-12-10
-
English Translations of Guidelines for Bioequivalence Studies of Generic Products
2021-09-14
-
Basic Concept on Bioequivalence Evaluation for Addition of Formulations with Different Dosage Forms in Ethical Kampo Formulations
2021-07-19
-
Basic principles on Utilization of Registry for Applications
2021-03-23
-
Points to Consider for Ensuring the Reliability in Utilization of Registry Data for Applications
2021-03-23
-
Guidelines for Analysis Reports Involving Physiologically based Pharmacokinetic Models
2020-12-21
-
Procedure for Remote Inspection as a part of compliance inspection on drugs and regenerative medical products
2020-11-16
-
On Release of Questions and Answers (Q&As) regarding the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents
2020-07-09
-
Considerations for the Clinical Evaluation of Drugs in Pediatric Patients (10 or 12 Years of Age and Older) Who Can be Evaluated Together with Adults
2020-06-30
-
Guideline for Exposure-Response Analysis of Drugs
2020-06-08
-
Guideline for preclinical safety assessment of oligonucleotide therapeutics
2020-03-30
-
Guideline on Ensuring the Quality and Safety of Gene Therapy Products
2019-07-09
同地域最新法律行政法规
-
Points to Consider for Informed Consent Using Electromagnetic Means in Clinical Trials and Post-marketing Clinical Trials
2023-03-30
-
Dr. Yasuhiro Fujiwara, Chief Executive of PMDA, re-elected Vice Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA) (News Release)
2022-07-19
-
Procedure for Remote Inspection as a Part of Compliance Inspection on Drugs and Regenerative Medical Products
2022-05-25
-
Amendment to “Basic Principles on Global Clinical Trials (Reference Cases)”
2021-12-10
-
English Translations of Guidelines for Bioequivalence Studies of Generic Products
2021-09-14
-
Basic Concept on Bioequivalence Evaluation for Addition of Formulations with Different Dosage Forms in Ethical Kampo Formulations
2021-07-19
-
Basic principles on Utilization of Registry for Applications
2021-03-23
-
Points to Consider for Ensuring the Reliability in Utilization of Registry Data for Applications
2021-03-23
-
Guidelines for Analysis Reports Involving Physiologically based Pharmacokinetic Models
2020-12-21
-
Procedure for Remote Inspection as a part of compliance inspection on drugs and regenerative medical products
2020-11-16
-
On Release of Questions and Answers (Q&As) regarding the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents
2020-07-09
-
Considerations for the Clinical Evaluation of Drugs in Pediatric Patients (10 or 12 Years of Age and Older) Who Can be Evaluated Together with Adults
2020-06-30
-
Guideline for Exposure-Response Analysis of Drugs
2020-06-08
-
Guideline for preclinical safety assessment of oligonucleotide therapeutics
2020-03-30
-
Guideline on Ensuring the Quality and Safety of Gene Therapy Products
2019-07-09
18983288589（微信同号）
18983288589（微信同号）
18908392210（微信同号）
18980413049
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: tyc7111cc太阳成集团 tyc7111cc太阳成集团企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网